OrbusNeich announces favorable ruling from European Patent Office OrbusNeich Medical announced that it received a favorable ruling from the European Patent Office yesterday in connection with its European Patent EP1 341 482. The '482 patent covers certain novel stents with helical structures. It was issued by the EPO to OrbusNeich in October 2010 and does not expire until December 2021. In July 2011, Boston Scientific Corporation and Terumo Kabushiki Kaisha filed oppositions asking the EPO to revoke the '482 patent, asserting that the patent was invalid.
Boston Scientific announces CE Mark for MRI labeling for ICD, CRT-D systems Boston Scientific has received CE Mark on magnetic resonance imaging conditional labeling for the current family of EL and MINI implantable cardioverter defibrillator and the X4 cardiac resynchronization therapy defibrillator systems. This revised labeling ensures that future patients and those already implanted with these systems are able to undergo MRI scans if indicated.